Literature DB >> 33044752

Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality.

Félicien Le Louedec1,2,3, Etienne Chatelut1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33044752      PMCID： PMC8108048          DOI： 10.1002/onco.13564

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.

Authors:  C Liu; J Yu; H Li; J Liu; Y Xu; P Song; Q Liu; H Zhao; J Xu; V E Maher; B P Booth; G Kim; A Rahman; Y Wang
Journal:  Clin Pharmacol Ther       Date:  2017-03-22       Impact factor: 6.875

2.  Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Authors:  Félicien Le Louedec; Catherine Alix-Panabières; Thierry Lafont; Ben C Allal; Renaud Garrel; Laurence Digue; Joël Guigay; Didier Cupissol; Jean-Pierre Delord; Benjamin Lallemant; Marc Alfonsi; Karine Aubry; Martine Mazel; François Becher; Françoise Perriard; Etienne Chatelut; Fabienne Thomas
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

3.  Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.

Authors:  David C Turner; Anna G Kondic; Keaven M Anderson; Andrew G Robinson; Edward B Garon; Jonathan Wesley Riess; Lokesh Jain; Kapil Mayawala; Jiannan Kang; Scot W Ebbinghaus; Vikram Sinha; Dinesh P de Alwis; Julie A Stone
Journal:  Clin Cancer Res       Date:  2018-06-11       Impact factor: 12.531

4.  Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.

Authors:  Morgane Caulet; Thierry Lecomte; Olivier Bouché; Jérôme Rollin; Valérie Gouilleux-Gruart; Nicolas Azzopardi; Julie Léger; Christophe Borg; Jean-Yves Douillard; Sylvain Manfredi; Denis Smith; Olivier Capitain; Aurélie Ferru; Driffa Moussata; Eric Terrebone; Gilles Paintaud; David Ternant
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

5.  Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.

Authors:  Apostolos Papachristos; Polychronis Kemos; Haralabos Kalofonos; Gregory Sivolapenko
Journal:  Oncologist       Date:  2020-04-28       Impact factor: 5.837

6.  Population pharmacokinetics of bevacizumab in cancer patients with external validation.

Authors:  Kelong Han; Thomas Peyret; Mathilde Marchand; Angelica Quartino; Nathalie H Gosselin; Sandhya Girish; David E Allison; Jin Jin
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-21       Impact factor: 3.333

7.  Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.

Authors:  Kelong Han; Jin Jin; Mauricio Maia; John Lowe; Martina A Sersch; David E Allison
Journal:  AAPS J       Date:  2014-06-19       Impact factor: 4.009
  7 in total
  1 in total

1.  In Reply.

Authors:  Apostolos Papachristos; Polychronis Kemos; Haralabos Kalofonos; Gregory Sivolapenko
Journal:  Oncologist       Date:  2020-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.